New Versiti Assay Evaluates Ability of a Patient’s Von Willebrand Factor (VWF) to bind to Collagen

New Versiti Assay Evaluates Ability of a Patient’s Von Willebrand Factor (VWF) to bind to Collagen

November 15, 2021

Research from the Blood Research Institute at Versiti has contributed to a new, novel assay which can more accurately evaluate the ability of a patient’s von Willebrand Factor (VWF) to support the clotting process, thereby helping physicians identify the cause of unexplained bleeding in some patients and guide appropriate treatment. 

Research conducted at Versiti’s Blood Research Institute, led to the development of the VWF Collagen IV Binding assay, or VWF:CBIV assay, which is now available for clinical order from Versiti Diagnostic Laboratories. With an extremely high degree of accuracy, the Collagen IV Binding Assay can identify rare bleeding phenotypes associated with VWF A1 domain sequence variations for type 1 von Willebrand Disease (VWD) and type 2M VWD. The addition of the VWF:CBIV assay makes Versiti’s von Willebrand Disease testing portfolio the most comprehensive panel available. Von Willebrand Disease is a complex disorder impacting up to 1% of the U.S. population.

“Defective VWF binding to type IV collagen is more prevalent in patients than defects in binding to type III collagen, and both collagen binding defects are associated with a bleeding phenotype in patients,” said Dr. Sandra Haberichter, director of hemostasis at Versiti and associate professor of pediatrics for the Medical College of Wisconsin. “The cause of bleeding in these patients is usually not detected due to lack of availability of assays. Our team at Versiti is proud to lead the way with this first-of-its-kind diagnostic test in the United States.” 

“I think that the most exciting aspect of the VWF Collagen IV Binding Assay is that there may be patients out there who have VWD due to a defect in collagen binding that current tests can’t diagnose, and this will help these patients to receive the correct diagnosis and treatment,” said Dr. Veronica Flood, professor of pediatric hematology/oncology with the Medical College of Wisconsin and associate investigator for the Blood Research Institute at Versiti. 

Although type 2M collagen binding defects are rare, defects in VWF binding to type IV collagen are more prevalent than defects in type III collagen binding.  

Related von Willebrand Assays
To establish clarity, Versiti’s existing VWF assay “VWF Collagen Binding Activity” has been renamed “VWF Collagen III Binding” (CBIII) (order code 1281). Von Willebrand Factor binds to collagen III binding through the VWF-A3 domain and the CBIII/Ag ratio is an excellent screen for multimeric defects. 

Comprehensive von Willebrand Disease Diagnostics
With the addition of the VWF Collagen IV Binding Assay, Versiti now offers the most extensive test options for the diagnosis of von Willebrand disease. Click here to view the evaluation algorithm.

For more information about the VWF:CBIV assay from the Blood Research Institute at Versiti, visit www.Versiti.org/CBIV.

 
Ohio State Kicks off Annual Blood Battle Oct. 27 with Goal of Beating Blood Shortage and Rival
Next Wednesday, October 27, marks the kickoff of the 40th Annual Blood Battle between The Ohio State University and “That Team Up North.” 
 
Versiti Announces Five State “Drive to Save Lives Sweepstakes”
Blood donors this holiday season will be entered to win an SUV; one winner per state
 
Media Kit
Versiti has created a library of resources designed to meet the unique needs of the media. Find Versiti media resources here
 
Press Releases
Important announcements, awards, urgent need and other important Versiti news.
 
Impact Stories
Your blood, organ and tissue, and other donations directly impact lives in your community. Read a few of the examples of some of the lives that have been changed for the better.
 
Ways to Give
You can support Versiti’s mission in several ways, including donating blood, hosting a blood drive, joining the organ and tissue donor registry, and more.